Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Effect of combination of interferon alpha-2b and interferon-gamma or interferon alpha-2b alone for elimination of SARS-CoV-2 viral RNA. Preliminary results of a randomized controlled clinical trial

Esquivel-Moynelo I Idelsis, Pérez-Escribano J, Duncan-Roberts Y, Vazquez-Blonquist D Dania, Bequet-Romero M, Baez-Rodríguez L, Castro-Ríos J, Cobas Cervantes L, Pagé-Calvet E, Travieso-Pérez S, Martinez-Suarez C, Campa-Legra I Ivan, Fernandez-Masso Julio Raul, Camacho-Rodriguez H, Díaz-Gálvez M, Sin-Mayor A, García-Sánchez M, Martínez-Martín SM, Alonso-Valdés M, Hernandez-Bernal F, Nodarse-Cuni H, Bello-Garcia D, Beato-Canfuk A, Vizcaino M Tania, Guillen-Nieto GE, Lucila Muzio-Gonzalez VL Verena, Bello-Rivero I
doi: https://doi.org/10.1101/2020.07.29.20164251
Esquivel-Moynelo I Idelsis
1Department of Medical Investigations, Direction of Technics and Science, Hospital Military Central Luis Díaz Soto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: iraldo.bello@cigb.edu.cu idelsisem@infomed.sld.cu abeato@infomed.sld.cu
Pérez-Escribano J
2Department of Clinical Laboratory, Direction of Technics and Science, Hospital Military Central Luis Díaz Soto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Duncan-Roberts Y
3Department of Clinical Investigations, Faculty Victoria de Giron, Scholl of Medicine Havana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vazquez-Blonquist D Dania
4Direction of Biomedical Research, Faculty Victoria de Giron, Scholl of Medicine Havana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bequet-Romero M
4Direction of Biomedical Research, Faculty Victoria de Giron, Scholl of Medicine Havana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Baez-Rodríguez L
5Department of Internal Medicine, Direction of Technics and Science, Hospital Military Central Luis Díaz Soto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Castro-Ríos J
6Department of Neurosurgery, Direction of Technics and Science, Hospital Military Central Luis Díaz Soto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cobas Cervantes L
7Department of Endocrinology, Direction of Technics and Science, Hospital Military Central Luis Díaz Soto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pagé-Calvet E
5Department of Internal Medicine, Direction of Technics and Science, Hospital Military Central Luis Díaz Soto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Travieso-Pérez S
5Department of Internal Medicine, Direction of Technics and Science, Hospital Military Central Luis Díaz Soto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martinez-Suarez C
5Department of Internal Medicine, Direction of Technics and Science, Hospital Military Central Luis Díaz Soto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Campa-Legra I Ivan
3Department of Clinical Investigations, Faculty Victoria de Giron, Scholl of Medicine Havana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fernandez-Masso Julio Raul
4Direction of Biomedical Research, Faculty Victoria de Giron, Scholl of Medicine Havana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Camacho-Rodriguez H
4Direction of Biomedical Research, Faculty Victoria de Giron, Scholl of Medicine Havana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Díaz-Gálvez M
1Department of Medical Investigations, Direction of Technics and Science, Hospital Military Central Luis Díaz Soto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sin-Mayor A
1Department of Medical Investigations, Direction of Technics and Science, Hospital Military Central Luis Díaz Soto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
García-Sánchez M
1Department of Medical Investigations, Direction of Technics and Science, Hospital Military Central Luis Díaz Soto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martínez-Martín SM
1Department of Medical Investigations, Direction of Technics and Science, Hospital Military Central Luis Díaz Soto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alonso-Valdés M
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hernandez-Bernal F
3Department of Clinical Investigations, Faculty Victoria de Giron, Scholl of Medicine Havana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nodarse-Cuni H
3Department of Clinical Investigations, Faculty Victoria de Giron, Scholl of Medicine Havana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bello-Garcia D
8Center for Genetic Engineering and Biotechnology; Faculty of Scholl of Medicine, Victoria de Giron, Havana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Beato-Canfuk A
9Department of Medical Investigations, Direction of Technics-Science, Hospital Military Central Luis Díaz Soto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: iraldo.bello@cigb.edu.cu idelsisem@infomed.sld.cu abeato@infomed.sld.cu
Vizcaino M Tania
1Department of Medical Investigations, Direction of Technics and Science, Hospital Military Central Luis Díaz Soto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guillen-Nieto GE
4Direction of Biomedical Research, Faculty Victoria de Giron, Scholl of Medicine Havana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lucila Muzio-Gonzalez VL Verena
3Department of Clinical Investigations, Faculty Victoria de Giron, Scholl of Medicine Havana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bello-Rivero I
3Department of Clinical Investigations, Faculty Victoria de Giron, Scholl of Medicine Havana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: iraldo.bello@cigb.edu.cu idelsisem@infomed.sld.cu abeato@infomed.sld.cu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Objectives An IFN-α2b and IFN-γ combination has demonstrated favorable pharmacodynamics for genes underlying antiviral activity which might be involved in the defense of a host from a SARS-CoV-2 infection. Considering this synergy, we conducted a randomized controlled clinical trial for efficacy and safety evaluation of subcutaneous IFN - α2b and IFN-γ administration in patients positive for SARS-CoV-2.

Methods We enrolled 19-82 years-old inpatients at the Military Central Hospital Luis Diaz Soto, Havana, Cuba. They were hospitalized after confirmed diagnosis for SARS-CoV-2 RNA by real-time reverse transcription polymerase chain reaction. Patients were randomly assigned in a 1:1 ratio to receive either, subcutaneous treatment with a co-lyophilized combination of 3.0 MIU IFN-α2b and 0.5 MIU IFN-γ (HeberFERON, CIGB, Havana, Cuba), twice a week for two weeks, or thrice a week intramuscular injection of 3.0 MIU IFN-α2b (Heberon® Alpha R, CIGB, Havana, Cuba). Additionally, all patients received lopinavir-ritonavir (200/50 mg every 12 h) and chloroquine (250 mg every 12 h, i.e.standard of care). The primary endpoints were, from the start of treatment, the time to elimination of viral RNA and the time to progression to severe COVID-19. The protocol was approved by the Ethics Committee on Clinical Investigation from the Hospital and the Center for the State Control of Medicines, Equipment and Medical Devices in Cuba. Informed consent was obtained from each participant (INSTITUTION PROTOCOL IG/IAG/CV/2001).

Results A total of 79 patients with laboratory-confirmed SARS-CoV-2 infection, including symptomatic or asymptomatic conditions, fulfilled the inclusion criteria and underwent randomization. Thirty-three subjects were assigned to the HeberFERON group, and 33 to the Heberon Alpha R group. Sixty-three patients were analyzed for viral elimination, of these 78.6% in the HeberFERON group eliminated the virus after 4 days of treatment versus 40.6% of patients in the Heberon Alpha R groups (p=0.004). Time to reach the elimination of SARS-CoV-2, as measured by RT-PCR was 3.0 and 5.0 days for the HeberFERON and Heberon Alpha R groups, respectively. A significant improvement in the reduction of time for virus elimination was attributable to HeberFERON (p=0.0027, Log-rank test) with a Hazard Ratio of 3.2 and 95% CI of 1.529 to 6.948, as compared to the Heberon Alpha R treated group.

Worsening of respiratory symptoms was detected in two (6.6%) and one (3.3%) patients in HeberFERON and IFN-α2b groups, respectively. However, none of the subjects transited to severe COVID-19 during the study or during the following clinical evaluation (21 more days).

RT-PCR on day 14 after the start of the treatment was negative to SARS-CoV-2 in 100% and 91% of patients of the combination of IFNs and IFN-α2b, respectively. Elimination in HeberFERON treated patients was related to a significant increase in lymphocytes counts and also a significant reduction in CRP as early as 7 days after commencing the therapeutic schedule.

All the patients in both cohorts recovered and had their laboratory parameters return to normal values by day 14 after treatment initiation. Adverse events were identified in 31.5% of patients, 28.5% in the control group, and 34.4% in the HeberFERON group, with the most frequent adverse event being headaches (17.4%).

Conclusions In a cohort of 63 hospitalized patients between 19 to 82 years-old with positive SARS-CoV-2, HeberFERON significantly eliminated the virus on day 4 of treatment when compared to treatment with IFN-α2b alone. However, Heberon Alpha R alone also showed efficacy for the treatment of the viral infection. Both treatments were safe and positively impacted on the resolution of the symptoms. None of the patients developed severe COVID-19.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

RPCEC00000307

Clinical Protocols

https://www.researcsquare.com./article/rs-28958/v1

Funding Statement

No payment has been received for any actions conserning the trial

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

MINISTRY OF PUBLIC HEALTH Approval of the Review and Ethical Committee Province: Havana Hospital: Military Central Luis Diaz Soto, Hospital The members of the Review and Ethical Committee of the hospital institution before mentioned and signing certified that: The clinical trial protocol Evaluation of the effect and safety of HeberFERON vs Heberon Alpha in patients infected with corona virus SARS-CoV-2 (Study ESPERANZA/HOPE). Code: IG/IAG/CV/2001; Version: 01; Data: 01 April 2020 Whose sponsor is the Center for genetic Engineering and Biotechnology, has been evaluated by the Committee from ethical, scientific and methodological point of view. a.The protocol complies with the requisites of suitability with respect to rights, safety, and welfare of the patients. b.The protocol complies with the requisites of suitability with respect to study objectives, justification of risks, management of adverse events, the information present d to de investigators about the product characteristics, CRF c.Are true both, the informed consent and procedures to be obtained

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • autor name corrected, text edited

Data Availability

The data are not available by now

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted August 04, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Effect of combination of interferon alpha-2b and interferon-gamma or interferon alpha-2b alone for elimination of SARS-CoV-2 viral RNA. Preliminary results of a randomized controlled clinical trial
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Effect of combination of interferon alpha-2b and interferon-gamma or interferon alpha-2b alone for elimination of SARS-CoV-2 viral RNA. Preliminary results of a randomized controlled clinical trial
Esquivel-Moynelo I Idelsis, Pérez-Escribano J, Duncan-Roberts Y, Vazquez-Blonquist D Dania, Bequet-Romero M, Baez-Rodríguez L, Castro-Ríos J, Cobas Cervantes L, Pagé-Calvet E, Travieso-Pérez S, Martinez-Suarez C, Campa-Legra I Ivan, Fernandez-Masso Julio Raul, Camacho-Rodriguez H, Díaz-Gálvez M, Sin-Mayor A, García-Sánchez M, Martínez-Martín SM, Alonso-Valdés M, Hernandez-Bernal F, Nodarse-Cuni H, Bello-Garcia D, Beato-Canfuk A, Vizcaino M Tania, Guillen-Nieto GE, Lucila Muzio-Gonzalez VL Verena, Bello-Rivero I
medRxiv 2020.07.29.20164251; doi: https://doi.org/10.1101/2020.07.29.20164251
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Effect of combination of interferon alpha-2b and interferon-gamma or interferon alpha-2b alone for elimination of SARS-CoV-2 viral RNA. Preliminary results of a randomized controlled clinical trial
Esquivel-Moynelo I Idelsis, Pérez-Escribano J, Duncan-Roberts Y, Vazquez-Blonquist D Dania, Bequet-Romero M, Baez-Rodríguez L, Castro-Ríos J, Cobas Cervantes L, Pagé-Calvet E, Travieso-Pérez S, Martinez-Suarez C, Campa-Legra I Ivan, Fernandez-Masso Julio Raul, Camacho-Rodriguez H, Díaz-Gálvez M, Sin-Mayor A, García-Sánchez M, Martínez-Martín SM, Alonso-Valdés M, Hernandez-Bernal F, Nodarse-Cuni H, Bello-Garcia D, Beato-Canfuk A, Vizcaino M Tania, Guillen-Nieto GE, Lucila Muzio-Gonzalez VL Verena, Bello-Rivero I
medRxiv 2020.07.29.20164251; doi: https://doi.org/10.1101/2020.07.29.20164251

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (230)
  • Allergy and Immunology (507)
  • Anesthesia (111)
  • Cardiovascular Medicine (1262)
  • Dentistry and Oral Medicine (207)
  • Dermatology (148)
  • Emergency Medicine (283)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (538)
  • Epidemiology (10055)
  • Forensic Medicine (5)
  • Gastroenterology (502)
  • Genetic and Genomic Medicine (2486)
  • Geriatric Medicine (240)
  • Health Economics (482)
  • Health Informatics (1653)
  • Health Policy (757)
  • Health Systems and Quality Improvement (638)
  • Hematology (250)
  • HIV/AIDS (538)
  • Infectious Diseases (except HIV/AIDS) (11896)
  • Intensive Care and Critical Care Medicine (627)
  • Medical Education (255)
  • Medical Ethics (75)
  • Nephrology (269)
  • Neurology (2304)
  • Nursing (140)
  • Nutrition (354)
  • Obstetrics and Gynecology (458)
  • Occupational and Environmental Health (537)
  • Oncology (1259)
  • Ophthalmology (377)
  • Orthopedics (134)
  • Otolaryngology (226)
  • Pain Medicine (158)
  • Palliative Medicine (50)
  • Pathology (326)
  • Pediatrics (737)
  • Pharmacology and Therapeutics (315)
  • Primary Care Research (282)
  • Psychiatry and Clinical Psychology (2295)
  • Public and Global Health (4850)
  • Radiology and Imaging (846)
  • Rehabilitation Medicine and Physical Therapy (493)
  • Respiratory Medicine (657)
  • Rheumatology (289)
  • Sexual and Reproductive Health (241)
  • Sports Medicine (228)
  • Surgery (273)
  • Toxicology (44)
  • Transplantation (131)
  • Urology (100)